Press release

Medivir presenting at DNB/Carnegie Healthcare Seminar

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative medical treatments in areas of high unmet medical need announces that the company will present at DNB/Carnegie Healthcare Seminar 2026, March 9, at 10.30 CET.

Strengthened by the recent rights issue and directed share issue to Carl Bennet AB, CEO Jens Lindberg will present an update as the company is kickstarting phase 2 clinical development of MIV-711 for Osteogenesis Imperfecta, a strategically important, new indication for the company, while continuing to progress the phase 2 development of fostrox in primary liver cancer. Two drug candidates with blockbuster potential and the opportunity to become the first, approved treatment option in the respective target patient population.

The presentation is live broadcasted and can be followed via the link; HERE.

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

About Medivir
Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir’s shareholders and affected patients. Collaborations and partnerships play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com